Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.61 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.61 |
| ▸ | IDO1 | P14902 | 3/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 14/20 | 0.53 |
| ▸ | IGF1R | P08069 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30019331 | 1.00 | PNMT (0.61) | PNMTTAAR1IDO1SIGMAR1IGF1R | |
| SCHEMBL79213 | 0.86 | IGF1R (0.58) | PNMTTAAR1IDO1SIGMAR1IGF1R | |
| SCHEMBL8211623 | 0.83 | IGF1R (0.59) | PNMTTAAR1IDO1SIGMAR1IGF1R | |
| SCHEMBL7009306 | 0.83 | IGF1R (0.59) | PNMTTAAR1IDO1SIGMAR1IGF1R | |
| SCHEMBL11389115 | 0.83 | IGF1R (0.59) | PNMTTAAR1IDO1SIGMAR1IGF1R | |
| SCHEMBL20570318 | 0.82 | PNMT (0.42) | PNMTTAAR1IDO1SIGMAR1IGF1R | |
| SCHEMBL2294256 | 0.82 | PNMT (0.42) | PNMTTAAR1IDO1SIGMAR1IGF1R | |
| SCHEMBL10830848 | 0.80 | CYP3A4 (0.43) | PNMTTAAR1SIGMAR1CYP1A2MEN1 | |
| SCHEMBL10977494 | 0.80 | CYP3A4 (0.63) | PNMTTAAR1IDO1SIGMAR1IGF1R | |
| SCHEMBL7458179 | 0.80 | PNMT (0.41) | PNMTTAAR1SIGMAR1IGF1RALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228502-A1 | 2-PHENYLAMINO PYRROLOPYRIMIDINES AS ACK1 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-07-11 | — | — | US | disclosed |
| WO-2022226290-A1 | 2-PHENYLAMINO PYRROLOPYRIMIDINES AS ACK1 INHIBITORS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-10-27 | — | — | WO | disclosed |
| US-20190031624-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | UNIV RUTGERS (US) | 2019-01-31 | — | — | US | disclosed |
| US-20190031624-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | UNIV RUTGERS (US) | 2019-01-31 | — | — | US | disclosed |
| CN-103732589-B | Can be used as the sulphonamide of the replacement of anti-apoptotic BCL inhibitor | BRISTOL-MYERS SQUIBB CO. (US) | 2016-03-30 | — | — | CN | disclosed |
| US-20150344503-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE, METHODS OF TREATMENT AND METHODS OF PREPARING SAME | INFINITY PHARMACEUTICALS INC (US) | 2015-12-03 | — | — | US | disclosed |
| CN-102395558-B | Aminotetralin derivatives, the pharmaceutical composition containing described Aminotetralin derivatives and purposes in the treatment thereof | ABBVIE (US) | 2015-09-02 | — | — | CN | disclosed |
| US-9108989-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| CN-102482221-B | bicyclic and tricyclic compounds as KATII inhibitors | PFIZER INC. (US) | 2014-10-22 | — | — | CN | disclosed |
| US-20140121183-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-5262420-A | Phenylalkylpyridines | IDEMITSU KOSAN CO., LTD. (JP) | 1993-11-16 | — | — | US | disclosed |
| EP-0505376-A1 | MUSCARINIC RECEPTOR ANTAGONISTS. | PFIZER LTD (GB) | 1992-09-30 | — | — | EP | disclosed |
| EP-0441852-A1 | MUSCARINIC RECEPTOR ANTAGONISTS. | PFIZER LTD (GB) | 1991-08-21 | — | — | EP | disclosed |
| WO-1991009013-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | PFIZER LIMITED (GB) | 1991-06-27 | — | — | WO | disclosed |
| EP-0383950-A1 | PYRIDINE DERIVATIVES AND INSECTICIDAL AND MITICIDAL AGENT CONTAINING SAME AS ACTIVE INGREDIENT | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1990-08-29 | — | — | EP | disclosed |
| EP-0376358-A1 | Muscarinic receptor antagonists | PFIZER INC. (US) | 1990-07-04 | — | — | EP | disclosed |
| WO-1990005133-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | PFIZER LIMITED (GB) | 1990-05-17 | — | — | WO | disclosed |
| US-4633026-A | DEHYDROHALOGENATION OF RING-HALOGENATED ALPHA- OR BETA-BROMOETHYL BENZENES WITH STRONG BASE, POLYOXYETHYLENE GLYCOL CATALYST, AMINE POLYMERIZATION INHIBITOR | ETHYL CORPORATION (US) | 1986-12-30 | — | — | US | disclosed |
| US-4292453-A | REACTION OF A HALO DERIVATIVE OF BETA-BROMOETHYLBENZENE WITH AQUEOUS ALKALI AND A QUATERNARY PHASE TRANSFER CATALYST | MAKHTESHIM CHEMICAL WORKS LTD. (IL) | 1981-09-29 | — | — | US | disclosed |
| US-4150135-A | ANALGESICS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1979-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031624-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | ABCB11, SLC10A1, SLC47A1 | PNMT 4205/4885TAAR1 3922/4885IDO1 3165/4885 |
| US-20240228502-A1 | 2-PHENYLAMINO PYRROLOPYRIMIDINES AS ACK1 INHIBITORS | ADCK1, DCK, TNKS2 | PNMT 4186/4885TAAR1 4717/4885IDO1 3888/4885 |
| US-20150344503-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE, METHODS OF TREATMENT AND METHODS OF PREPARING SAME | FAAH, FAAH2, ASAH1 | PNMT 972/4885TAAR1 745/4885IDO1 314/4885 |
| US-20140121183-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | PNMT 1118/4885TAAR1 616/4885IDO1 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.